Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A. Lockhart AC, et al. Among authors: dash ab. Invest New Drugs. 2019 Feb;37(1):87-97. doi: 10.1007/s10637-018-0610-0. Epub 2018 May 21. Invest New Drugs. 2019. PMID: 29781056 Free PMC article. Clinical Trial.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR. Swords RT, et al. Among authors: dash ab. Blood. 2018 Mar 29;131(13):1415-1424. doi: 10.1182/blood-2017-09-805895. Epub 2018 Jan 18. Blood. 2018. PMID: 29348128 Free PMC article. Clinical Trial.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Among authors: dash ab. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
Chng WJ, Lonial S, Morgan GJ, Iida S, Moreau P, Kumar SK, Twumasi-Ankrah P, Villarreal M, Dash AB, Vorog A, Zhang X, Suryanarayan K, Labotka R, Dimopoulos MA, Rajkumar SV. Chng WJ, et al. Among authors: dash ab. Blood Cancer J. 2023 Jan 12;13(1):14. doi: 10.1038/s41408-022-00768-5. Blood Cancer J. 2023. PMID: 36631458 Free PMC article.
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, Ghobrial IM, Gormley NJ, Gupta I, Higley H, Hillengass J, Kanapuru B, Kazandjian D, Kelloff GJ, Kirsch IR, Kremer B, Landgren O, Lightbody E, Lomas OC, Lonial S, Mateos MV, Montes de Oca R, Mukundan L, Munshi NC, O'Donnell EK, Orfao A, Paiva B, Patel R, Pugh TJ, Ramasamy K, Ray J, Roshal M, Ross JA, Sigman CC, Thoren KL, Trudel S, Ulaner G, Valente N, Weiss BM, Zamagni E, Kumar SK. Anderson KC, et al. Clin Cancer Res. 2021 Oct 1;27(19):5195-5212. doi: 10.1158/1078-0432.CCR-21-1059. Clin Cancer Res. 2021. PMID: 34321279 Free PMC article.
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Paiva B, Manrique I, Dimopoulos MA, Gay F, Min CK, Zweegman S, Špička I, Teipel R, Mateos MV, Giuliani N, Cavo M, Hopkins CR, Fu W, Suryanarayan K, Vorog A, Li C, Wang B, Estevam J, Labotka R, Dash AB. Paiva B, et al. Among authors: dash ab. Blood. 2023 Feb 9;141(6):579-591. doi: 10.1182/blood.2022016782. Blood. 2023. PMID: 36130300 Free PMC article.
Molecular genetics of acute myeloid leukaemia.
Dash A, Gilliland DG. Dash A, et al. Best Pract Res Clin Haematol. 2001 Mar;14(1):49-64. doi: 10.1053/beha.2000.0115. Best Pract Res Clin Haematol. 2001. PMID: 11355923 Review.
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma.
Bruins WSC, Rentenaar R, Newcomb J, Zheng W, Ruiter RWJ, Baardemans T, Poma E, Moore C, Robinson GL, Lublinsky A, Zhang Y, Syed S, Milhollen M, Dash AB, van de Donk NWCJ, Groen RWJ, Zweegman S, Mutis T. Bruins WSC, et al. Among authors: dash ab. Hemasphere. 2024 Nov 14;8(11):e70039. doi: 10.1002/hem3.70039. eCollection 2024 Nov. Hemasphere. 2024. PMID: 39544624 Free PMC article.
15 results